N-cyclohexyl-3-methyl-2-oxobutanamide | 32998-89-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-cyclohexyl-3-methyl-2-oxobutanamide
• 英文别名: N-Cyclohexyl-3-methyl-2-oxobutyramid
• CAS: 32998-89-3
• 化学式: C₁₁H₁₉NO₂
• 分子量: 197.277
• InChiKey: YIXGRJQSBFKTGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-cyclohexyl-2-(propan-2-yl)imidazo[1,2-a]pyridin-3-amine 在 4-methylbenzenesulfonic acid hydrate 、 碘苯二乙酸 作用下， 反应 1.0h， 以79.9%的产率得到N-cyclohexyl-3-methyl-2-oxobutanamide
  参考文献：
  名称：

  一种α-羰基酰胺衍生物的制备方法

  摘要：

  本发明公开了一种α‑羰基酰胺衍生物的制备方法，即：采用吡啶并咪唑胺类化合物与水在氧化剂作用下发生开环反应，同时插入氧原子，制备得到α‑羰基酰胺衍生物的方法。本方法操作简单，底物普适性广，反应过程中无金属催化，不需要无水无氧的条件，其结构中“O”原子来源于水，副产物可作为制备本发明所采用吡啶并咪唑胺类的原料，从而实现其再循环利用。本方法还具有收率高、可用于大量制备α‑羰基酰胺衍生物和制备部分现有方法中较难制备α‑羰基酰胺衍生物等优点。

  公开号：

  CN109096139B

文献信息

• Inhibitors of cysteine proteases and methods of use thereof
  申请人：Pardes Biosciences, Inc.

  公开号：US11124497B1

  公开（公告）日：2021-09-21

  The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Exemplary compounds provided include Formula II-I, where R3, RB are provided herein:

  该披露提供了具有战斗头的化合物及其在治疗医学疾病或紊乱，如病毒感染方面的用途。提供了制药组合物和制备各种带有战斗头的化合物的方法。这些化合物被认为能够抑制蛋白酶，如3C、CL-或3CL样蛋白酶。提供的示例化合物包括Formula II-I，其中R3、RB如下所示：
• Functionalized peptides as antiviral agents
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US11358953B2

  公开（公告）日：2022-06-14

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了式（I）化合物及其药学上可接受的盐类： 其可抑制冠状病毒的复制活性。本发明进一步涉及包含式（I）化合物或其药学上可接受的片剂的药物组合物，以及治疗或预防有需要的受试者感染冠状病毒的方法，包括向受试者施用治疗有效量的式（I）化合物或其药学上可接受的盐。
• Diverse Oxidative C(sp²)–N Bond Cleavages of Aromatic Fused Imidazoles for Synthesis of α-Ketoamides and <i>N</i>-(pyridin-2-yl)arylamides
  作者：Fangzhou Xu、Yanyan Wang、Xiwei Xun、Yun Huang、Zhichao Jin、Baoan Song、Jian Wu

  DOI：10.1021/acs.joc.9b00208

  日期：2019.7.5

  An efficient and chemoselective C(sp(2))-N bond cleavage of aromatic imidazo[1,2-a]pyridine molecules is developed. A broad scope of amide compounds such as alpha-ketoamides and N-(pyridin-2-yl)arylamides are afforded as the final products in up to quantitative yields. Diverse C-N bond cleavages are controlled by the oxidative species used in this transformation, with various amide products afforded in a chemoselective fashion. A preliminary study indicated that some alpha-ketoamides exhibit anti-Tobacco Mosaic Virus activity for potential use in plant protection.
• FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20220033383A1

  公开（公告）日：2022-02-03

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
• INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
  申请人：Pardes Biosciences, Inc.

  公开号：US20220162194A1

  公开（公告）日：2022-05-26

  The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.